CS1003's CTA filing was entered into the new process by the CNDA and approved after less than four months of review by the Center for Drug Evaluation. CStone will initiate a multi-center Phase I clinical trial to assess the safety, tolerability and preliminary anti-tumor activity of CS1003 in Chinese patients with advanced cancers. "We are pleased to begin the development of CS1003 in China, which follows a first-in-human dose escalation trial initiated in Australia in May this year ," said Dr. Frank Jiang, Chief Executive Officer at CStone. "The start of clinical evaluation for CS1003 in China is an important step in the development path for this molecule, which is a key component of CStone's immunotherapy strategy and will form the backbone of combination therapies.